

PROVIDER Update



Health Net®

CONTRACTUAL | MAY 24, 2019 | UPDATE 19-387 | 3 PAGES

Injectable Medication HCPCS/DOFR Crosswalk Reference Table Update – 2nd Quarter 2019

Approved updates are effective June 30, 2019

On April 16, 2019, the Health Net* Pharmacy and Therapeutics (P&T) Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk.

The approved updates are effective June 30, 2019, and listed on pages 2 and 3. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net *Provider Participation Agreement (PPA)*.

The update includes:

- DOFR categories for eight new injectable medications (that can be billed using 10 HCPCS codes).
- HCPCS code changed for one injectable medication.
- Addition of secondary category for 10 existing injectable medications.

ADDITIONAL INFORMATION

Relevant sections of Health Net's provider operations manuals have been revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library, located on Health Net's provider website as listed in the right-hand column.

If you have questions regarding the information contained in this update, contact the Health Net Provider Services Center by email at provider_services@healthnet.com within 60 days, by telephone or through the Health Net provider website as listed in the right-hand column.

THIS UPDATE APPLIES TO CALIFORNIA PROVIDERS:

- Physicians
- Participating Physician Groups
- Hospitals
- Ancillary Providers

LINES OF BUSINESS:

- HMO/POS/HSP
- PPO
- EPO
- Medicare Advantage (HMO)
- Medi-Cal
 - Kern
 - Los Angeles
 - Molina
 - Riverside
 - Sacramento
 - San Bernardino
 - San Diego
 - San Joaquin
 - Stanislaus
 - Tulare

PROVIDER SERVICES

provider_services@healthnet.com

Health Net Employer Group HMO, POS, HSP

1-800-641-7761

provider.healthnet.com

IFP – CommunityCare HMO, PureCare HSP

1-888-926-2164

provider.healthnetcalifornia.com

Medicare (individual)

1-800-929-9224

provider.healthnetcalifornia.com

Medicare (employer group)

1-800-929-9224

provider.healthnet.com

Medi-Cal – 1-800-675-6110

provider.healthnet.com

PROVIDER COMMUNICATIONS

provider.communications@healthnet.com

* Health Net of California, Inc. and Health Net Community Solutions, Inc. are subsidiaries of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved. CONFIDENTIALITY NOTE FOR FAX TRANSMISSION: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please notify the sender immediately by telephone or by return fax and destroy this transmission, along with any attachments.

ADDITIONS TO INJECTABLE MEDICATION HCPCS/DOFR CROSSWALK

The following medications have been approved by the Health Net P&T Committee as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table. P&T Committee members include physicians and representatives from Health Net participating physician groups (PPGs).

New Drugs:

HCPCS	Drug Name	Generic Name	Primary Category	Secondary Category
J3590	Cablivi®	Caplacizumab-yhdp	Self-injectable	
J3490	Clorotekal®	Chloroprocaine hydrochloride injection, for intrathecal use	Therapeutic inj	
J9999	Elzonris™	Tagraxofusp-erzs injection, for intravenous use	Therapeutic inj	Chemotherapy
90739	Hepilisav-b®	Hepatitis B vaccine (recombinant), adjuvanted] solution for intramuscular injection	Therapeutic inj	Immunizations
J3590	Nuzyra™	Omadacycline for injection	Therapeutic inj	
C9399, J3590	Revcovi™	Elapegademase-lvlr injection, for intramuscular use	Therapeutic inj	
J3590	Ultomiris™	Ravulizumab-cwvz injection, for intravenous use	Therapeutic inj	
J3490	Xerava™	Eravacycline dihydrochloride injection, for intravenous use	Therapeutic inj	

UPDATES/CHANGES TO INJECTABLE MEDICATION PROCEDURE CODES OR MEDICATIONS

Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk.

Updates:

HCPCS	Drug Name	Generic Name	Comment
J7329	Trivisc™	Sodium hyaluronate	Changed from J3490

CATEGORY CHANGES TO HCPCS CROSSWALK

Secondary category additions were made to the HCPCS crosswalk for the following existing injectable medications.

Category Changes:

HCPCS	Drug Name	Generic Name	Primary Category	Secondary Category
J0714	Avycaz®	Ceftazidime-avibactam Injection	Therapeutic inj	Home health/infusion**
J1743	Elaprase®	Idursulfase, 1 mg	Therapeutic inj	Home health/infusion**
J3380	Entyvio™	Vedolizumab for injection, for intravenous use	Therapeutic inj	Home health/infusion**

CATEGORY CHANGES TO HCPCS CROSSWALK, continued

HCPCS	Drug Name	Generic Name	Primary Category	Secondary Category
Q5109				
J2480				
C9399, J9999				
J3358				
J2185				
J1322				
C9399, J3490				

*HCPCS codes were taken from the Centers for Medicare & Medicaid Services (CMS) HCPCS website at www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html.

**When administered by a nurse in a home setting.